The mission of the Delaware BioScience Association is to become the catalyst to ensure Delaware becomes a global leader in life sciences by developing a cohesive community that unites the region's biotechnology, pharmaceutical, research, financial and agricultural strengths.
Delaware's bioscience industry is one of the strongest per capita in the United States. Coupled with its neighboring states of Pennsylvania and New Jersey, the tri-state region represents 80% of the US pharmaceuticals industry. Strong academic research institutions working collaboratively with medical institutions and industry develop and commercialize many of the blockbuster drugs and the most innovative diagnostics and medical devices found anywhere in the world. All within a 50-mile radius and within a one to two-hour drive of each other.
Global bioscience industry giants with significant Delaware research and or manufacturing operations include Agilent Technologies, AstraZeneca Pharmaceuticals, DuPont, Johnson & Johnson, Merck, Siemens Healthcare Diagnostics, W.L. Gore and within an hour's commute include Cephalon, Centocor, CSL Behring, Endo Pharmaceuticals, GSK, Pfizer, Sanofi-Aventis and more.
Meet Our Team
Jamie Pedrick joined the Delaware Bio team in…
Helen Stimson President & CEO Delaware BioScience Association…
Ruby Harrington has worked with Delaware Bio for…
Our Action Plan:
Actions taken to promote development include:
Beginning in 2004, representatives from a cross-section of bioscience enterprises met under the direction of Governor Ruth Ann Minner to develop recommendations for further growth, involving activities that both the public and private sector could undertake.
The Delaware Bioscience Industry Cluster met several times to identify issues affecting Delaware's competitiveness in the biosciences, explore opportunities, and develop recommendations for moving forward. The Cluster was co-chaired by Catherine M. Bonuccelli, M.D., Vice President of External Scientific Affairs for AstraZeneca Pharmaceuticals; T. Ben Hsu, Ph.D., Vice President of Finance and Control for Quest Pharmaceutical Services; and Ray Yin, Ph.D., President & CTO, ANP Technologies.
One of the Cluster's key recommendations to the Governor was the formation of a trade association, which could capitalize on the strength of collaboration to foster growth of the bioscience sector.
As a result, the Delaware BioScience Association was formed in early 2006, bringing together pharmaceutical and biotechnology firms, medical device manufacturers, agricultural biotech and chemical companies, research and testing companies, hospitals and medical institutions, and other organizations and related service companies, with the shared goal of expanding an already vibrant bioscience economy.
Accelerating Member Success
Providing personalized attention and facilitating connections to support ur members to solve problems and create new possibilities.
Deliver high impact programs and events that build skills, expand networks, and increase knowledge of work happening in our vibrant community.
Save members money on daily business operations. We accomplish this by offering access to our national Bio Business Solutions buying consortium programs and by exercising our buying power locally to strike the best deals for members.
Advocate for our industry on both the state and federal levels. Our current focus is to evaluate and articulate Delaware’s competitiveness for bioscience companies relative to other states and to advocate for improvements.
The Delaware BioScience Association is a 501 ©6 organization representing more then 100 member companies, service providers, and research institutions.